Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536349 | 0.79 | AKR1C3 (0.44) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL30231208 | 0.79 | AKR1C3 (0.44) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL28059708 | 0.76 | CES2 (0.45) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL5151815 | 0.73 | AKR1C3 (0.40) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL8823987 | 0.71 | AKR1C3 (0.36) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL16963923 | 0.71 | CES2 (0.46) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL29010117 | 0.71 | KEAP1 (0.47) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL30427742 | 0.70 | KCNQ2 (0.49) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL1966206 | 0.70 | KCNQ2 (0.49) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL19200334 | 0.70 | AKR1C3 (0.50) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | AKR1C3 3440/4885AKR1C2 3634/4885AKR1C1 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.